Stryker (SYK) Expected to Announce Earnings on Tuesday

Stryker (NYSE:SYK) is expected to post its quarterly earnings results after the market closes on Tuesday, January 28th. Analysts expect Stryker to post earnings of $3.87 per share and revenue of $6,358,730.00 billion for the quarter. Stryker has set its FY 2024 guidance at 12.000-12.100 EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. During the same period in the prior year, the firm earned $2.46 EPS. The business’s quarterly revenue was up 11.9% on a year-over-year basis. On average, analysts expect Stryker to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Stryker Trading Up 0.1 %

NYSE:SYK opened at $394.08 on Monday. Stryker has a 12-month low of $307.23 and a 12-month high of $398.20. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The business has a 50 day simple moving average of $376.11 and a 200 day simple moving average of $360.98. The firm has a market capitalization of $150.23 billion, a P/E ratio of 42.24, a P/E/G ratio of 2.68 and a beta of 0.95.

Stryker Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.85%. This is a positive change from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio is currently 36.01%.

Insider Buying and Selling

In related news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on SYK. Citigroup boosted their target price on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Wednesday, January 22nd. Royal Bank of Canada restated an “outperform” rating and issued a $425.00 target price on shares of Stryker in a research report on Tuesday, January 7th. Canaccord Genuity Group boosted their price target on Stryker from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, JMP Securities reissued a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $405.80.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.